Orchard Therapeutics Plc (ORTX) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Orchard Therapeutics Unveils New Strategic Plan and Reports First Quarter 2020 Financial Results
May 7, 2020 7:01 AM EDTPortfolio Investments More Tightly Prioritized Around High Need, High Value Indications
First Disease Targets Extending Platform into Less Rare Indications Disclosed
Updated Timelines Provided for MLD and MPS-I Programs
California Facility Investment Terminated with Near-term Manufacturing Capacity Secured
Expected Savings of Approximately $125M, Extending Cash Runway into 2022
BOSTON and LONDON, May 07, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a new strategic... More
